Rituximab vedotin in the frontline setting: Dr Stephen Ansell
Listen now
Description
Dr Stephen Ansell talks to ecancer at ASCO 2013 about rituximab vedotin, an anti-CD30 chemotherapy agent, which allows for chemotherapy to be administered directly into malignant cells. Rituximab vedotin has shown promising results in lymphoma as a single agent and is currently in clinical trials investigating use in combination in the frontline setting.
More Episodes
Dr Mario Sznol talks to ecancer at ASCO 2013 about long-term follow-up results from an expanded phase I study examining the effects of nivolumab in advanced melanoma.
107 patients were treated with five different doses of nivolumab. All patients had disease that worsened despite prior standard...
Published 06/13/13
Dr Swchwartz gives ecancertv his ASCO 2013 highlights. He covers the latest promising news in melanoma and comments on the potential of immunotherapy and antibodies for treatment of other cancers.
Published 06/13/13
Dr Matthew Ellis talks to ecancer at ASCO 2013 about the affects of The Cancer Genome Atlas on research, treatment and next generation sequencing.
Published 06/13/13
Links
No website
No RSS feed
Twitter
Facebook
Instagram
Patreon
Genres
Artwork or description wrong?
Request an update »
Updates may take a few minutes.
Do you host a podcast?
Track your ranks and reviews from Spotify, Apple Podcasts and more.
See hourly chart positions and more than 30 days of history.
Get Chartable Analytics »
See hourly chart positions and more than 30 days of history.
